免疫治疗联合化疗治疗晚期肺癌的进展

Advances in chemotherapy combined with immunotherapy for advanced lung cancer

近年来,免疫单药治疗肺癌的疗效显著。许多基础研究和临床研究的结果均表明,免疫治疗联合化疗可能取得较单一疗法更加优异的疗效。化疗可能直接刺激先天性免疫反应和获得性免疫细胞,阻断促进肿瘤进展的免疫抑制通路,提高肿瘤细胞的抗原性或免疫原性,或者加强免疫效应机制的敏感性。目前,免疫治疗联合化疗的临床研究正在进行之中,但不良反应亦不容忽视,如何确定更佳组合方案,仍需进一步的研究。

Recent studies have showed that the single immunotherapy could get excellent therapeutic effect on lung cancer. A large number of basic and clinical studies have showed that the combination of chemotherapy and immunotherapy may have better efficacy than single therapy. Chemotherapy may stimulate the innate immune response and the acquired immune cells directly, block the immune suppressive pathways which promote tumor progression, enhance tumor cell antigenicity or immunogenicity, or enhance the sensitivity of immune effect. At present, the clinical research on combination of chemotherapy and immunotherapy is in progress, but the side effects should not be ignored.